<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36160133</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors.</ArticleTitle><Pagination><StartPage>975930</StartPage><MedlinePgn>975930</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">975930</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.975930</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Psychotropic drug consumption has increased during the COVID-19 pandemic. We describe here the prevalence and identifying factors associated with Benzodiazepine (BZD) and Z-hypnotics use among a sample of Spanish adults suffering from long-COVID-19 syndrome, from a gender perspective.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Data were anonymously collected between 15th December 2021 and 15th March 2022. The collection form consisted of several questions gathering sociodemographic information, post-COVID symptom, health profile, and pharmacological drug intake. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on self-medicated consumption. Three models were generated (female, male, and both gender).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Prevalence of BZD and Z-hypnotics use was 44.9% (46.5% for women; 37.8% for men). Zolpidem was the most consumed drug among male (20.7%), and lorazepam in female (31.1%). Patterns of drug consumption among female were related with number of post-COVID symptoms and smoking habit (AOR 2.76, 95%CI 1.16-6.52). Males under 40 years of age are more likely to consume BZD and Z-hypnotics (AOR 5.52, 95%CI 1.08-28.27).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The prevalence of consumption of BZD and Z-hypnotics in those subjects with long-COVID-19 in our study reaches values of 44.9%. Women with long-COVID-19 declare a higher prevalence of consumption than men. Predictors of BZD and Z-hypnotic in men were, age and number of medication use. Smoking habit and the number of post-COVID symptoms were predictive variables in women.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Carrasco-Garrido, Fern&#xe1;ndez-de-Las-Pe&#xf1;as, Hern&#xe1;ndez-Barrera, Palacios-Ce&#xf1;a, Jim&#xe9;nez-Trujillo and Gallardo-Pino.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrasco-Garrido</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Barrera</LastName><ForeName>Valent&#xed;n</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacios-Ce&#xf1;a</LastName><ForeName>Domingo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Trujillo</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo-Pino</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Z-hypnotics</Keyword><Keyword MajorTopicYN="N">benzodiazepine</Keyword><Keyword MajorTopicYN="N">gender</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword><Keyword MajorTopicYN="N">predictors</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>17</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36160133</ArticleId><ArticleId IdType="pmc">PMC9493021</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.975930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO, WHO Coronavirus (COVID-19) Dashboard. (2022). Available online at: https://covid19.who.int/ (accessed May 10, 2022).</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#x131; A, Bernabei R, Landi F. Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, G&#xf3;mez-Mayordomo V, Cuadrado ML, Palacios-Ce&#xf1;a D, Florencio LL, Guerrero AL, et al. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: a case-control study. Cephalalgia. (2021) 41:1332&#x2013;41. 10.1177/03331024211020404</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03331024211020404</ArticleId><ArticleId IdType="pmc">PMC8212025</ArticleId><ArticleId IdType="pubmed">34134526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandola T, Kumari M, Booker CL, Benzeval M. The mental health impact of COVID-19 and lockdown-related stressors among adults in the UK. Psychol Med. (2020) 7:1&#x2013;10. 10.1017/S003329172000504</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329172000504</ArticleId><ArticleId IdType="pmc">PMC7783135</ArticleId><ArticleId IdType="pubmed">33280639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford T, John A, Gunnell D. Mental health of children and young people during pandemic. BMJ. (2021) 372:n614. 10.1136/bmj.n614</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n614</ArticleId><ArticleId IdType="pubmed">33692087</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;uerle A, Steinbach J, Schweda A, Beckord J, Hetkamp M, Weism&#xfc;ller B, et al. Mental health burden of the COVID-19 outbreak in Germany: predictors of mental health impairment. J Prim Care Commun Health. (2020) 11:215013272095 3682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7457643</ArticleId><ArticleId IdType="pubmed">32865107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain MM, Tasnim S, Sultana A, Faizah F, Mazumder H, Zou L, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Research. (2020) 9:636. 10.12688/f1000research.24457.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.24457.1</ArticleId><ArticleId IdType="pmc">PMC7549174</ArticleId><ArticleId IdType="pubmed">33093946</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LZ, Wang S. Prevalence and predictors of general psychiatric disorders and loneliness during COVID-19 in the United Kingdom. Psychiatry Res. (2020) 291:113267. 10.1016/j.psychres.2020.113267</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113267</ArticleId><ArticleId IdType="pmc">PMC7326403</ArticleId><ArticleId IdType="pubmed">32623266</ArticleId></ArticleIdList></Reference><Reference><Citation>Reppas-Rindlisbacher C, Mahar A, Siddhpuria S, Savage R, Hallet J, Rochon P. Gender differences in mental health symptoms among Canadian older adults during the COVID-19 pandemic: a cross-sectional survey. Can Geriatr J. (2022) 25:49&#x2013;56. 10.5770/cgj.25.532</Citation><ArticleIdList><ArticleId IdType="doi">10.5770/cgj.25.532</ArticleId><ArticleId IdType="pmc">PMC8887702</ArticleId><ArticleId IdType="pubmed">35310469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schecke H, Fink M, B&#xe4;uerle A, Skoda EM, Schweda A, Musche V, et al. Changes in substance use and mental health burden among women during the second wave of COVID-19 in Germany. Int J Environ Res Public Health. (2021) 18:9728. 10.3390/ijerph18189728</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18189728</ArticleId><ArticleId IdType="pmc">PMC8471041</ArticleId><ArticleId IdType="pubmed">34574651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sociological Research Center (CIS), Spanish Mental Health is fine. Survey during COVID-19 Pandemic. Results Preview. (2021). Available online at: https://www.consaludmental.org/publicaciones/Encuesta-salud-mental-covid19-cis-avance-resultados.pdf (accessed August 8, 2022).</Citation></Reference><Reference><Citation>Bednarczyk E, Cook S, Brauer R, Garfield S. Stakeholders&#x2019; views on the use of psychotropic medication in older people: a systematic review. Age Ageing. (2022) 51:afac060. 10.1093/ageing/afac060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afac060</ArticleId><ArticleId IdType="pmc">PMC8934150</ArticleId><ArticleId IdType="pubmed">35305087</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani SA, Raji MA, Chen L, Kuo YF. Trends in the use of benzodiazepines. Z-Hypnotics, and serotonergic drugs among US women and men before and during the COVID-19 pandemic. JAMA Netw Open. (2021) 4:e2131012. 10.1001/jamanetworkopen.2021.31012</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.31012</ArticleId><ArticleId IdType="pmc">PMC8546497</ArticleId><ArticleId IdType="pubmed">34694388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes S, Sosa-Napolskij M, Lobo G, Silva I. Impact of the COVID-19 pandemic in the Portuguese population: consumption of alcohol, stimulant drinks, illegal substances, and pharmaceuticals. PLoS One. (2021) 16:e0260322. 10.1371/journal.pone.0260322</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260322</ArticleId><ArticleId IdType="pmc">PMC8604309</ArticleId><ArticleId IdType="pubmed">34797874</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonazzo IC, Fornari C, Maumus-Robert S, Cei E, Paoletti O, Ferrara P, et al. Antidepressants drug use during COVID-19 waves in the tuscan general population: an interrupted time-series analysis. J Pers Med. (2022) 12:178. 10.3390/jpm12020178</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12020178</ArticleId><ArticleId IdType="pmc">PMC8879880</ArticleId><ArticleId IdType="pubmed">35207666</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Pellicer-Valero OJ, Navarro-Pardo E, Rodr&#xed;guez-Jim&#xe9;nez J, Mart&#xed;n-Guerrero JD, Cigar&#xe1;n-M&#xe9;ndez M. The number of symptoms at the acute COVID-19 phase is associated with anxiety and depressive long-term post-COVID symptoms: a multicenter study. J Psychosom Res. (2021) 150:110625. 10.1016/j.jpsychores.2021.110625</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2021.110625</ArticleId><ArticleId IdType="pmc">PMC8455234</ArticleId><ArticleId IdType="pubmed">34563747</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Mart&#xed;n-Guerrero JD, Pellicer-Valero &#xd3;J, Navarro-Pardo E, G&#xf3;mez-Mayordomo V, Cuadrado ML, et al. Female sex is a risk factor associated with long-term post-covid related-symptoms but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study. J Clin Med. (2022) 11:413. 10.3390/jcm11020413</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020413</ArticleId><ArticleId IdType="pmc">PMC8778106</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gender-Net.
Manuals with Guidelines on the Integration of Sex and Gender Analysis into Research Contents, Recommendations for Curricula Development and Indicators. (2016). Available online at: http://www.gender-net.eu/?lang=en (accessed April 7, 2022)</Citation></Reference><Reference><Citation>Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Third ed. Hoboken, NJ: John Wiley &amp; Sons, Inc; (2013).</Citation></Reference><Reference><Citation>S&#xe1;nchez D&#xed;az M, Mart&#xed;n-Calvo ML, Mateos-Campos R. Trends in the use of anxiolytics in Castile and Leon, Spain, between 2015-2020: evaluating the impact of COVID-19. Int J Environ Res Public Health. (2021) 18:5944. 10.3390/ijerph18115944</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18115944</ArticleId><ArticleId IdType="pmc">PMC8198623</ArticleId><ArticleId IdType="pubmed">34205985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-L&#xf3;pez MDC, D&#xed;az-Calvo V, Ru&#xed;z-Gonz&#xe1;lez C, Nievas-Soriano BJ, Rebollo-Lavado B, Parr&#xf3;n-Carre&#xf1;o T. Consumption of psychiatric drugs in primary care during the COVID-19 Pandemic. Int J Environ Res Public Health. (2022) 19:4782. 10.3390/ijerph19084782</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19084782</ArticleId><ArticleId IdType="pmc">PMC9030027</ArticleId><ArticleId IdType="pubmed">35457647</ArticleId></ArticleIdList></Reference><Reference><Citation>Agencia Espa&#xf1;ola de Medicamentos y Productos Sanitarios, Utilizaci&#xf3;n de Medicamentos. Ansiol&#xed;ticos E Hipn&#xf3;ticos En Espa&#xf1;a. (2022). Available online at: https://www.aemps.gob.es/medicamentos-de-uso-humano/observatorio-de-uso-de-medicamentos/informes-ansioliticos-hipnoticos/ (accessed May 18, 2022).</Citation></Reference><Reference><Citation>Meng X, D&#x2019;Arcy C, Tempier R. Trends in psychotropic use in Saskatchewan from 1983 to 2007. Can J Psychiatry. (2013) 58:426&#x2013;31. 10.1177/070674371305800708</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/070674371305800708</ArticleId><ArticleId IdType="pubmed">23870725</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco-Garrido P, Hern&#xe1;ndez-Barrera V, Jim&#xe9;nez-Trujillo I, Esteban-Hern&#xe1;ndez J, &#xc1;lvaro-Meca A, L&#xf3;pez-de Andr&#xe9;s A, et al. Time trend in psychotropic medication use in Spain: a nationwide population-based study. Int J Environ Res Public Health. (2016) 13:1177. 10.3390/ijerph13121177</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13121177</ArticleId><ArticleId IdType="pmc">PMC5201318</ArticleId><ArticleId IdType="pubmed">27886138</ArticleId></ArticleIdList></Reference><Reference><Citation>Estancial Fernandes CS, de Azevedo RCS, Goldbaum M, Barros MBA. Psychotropic use patterns: are there differences between men and women? PLoS One. (2018) 13:e0207921. 10.1371/journal.pone.0207921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0207921</ArticleId><ArticleId IdType="pmc">PMC6257918</ArticleId><ArticleId IdType="pubmed">30475871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. (2022) 28:611.e9&#x2013;16. 10.1016/j.cmi.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. (2022) 13:1957. 10.1038/s41467-022-29521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz Cantero MT. Health statistics and invisibility by sex and gender during the COVID-19 epidemic. Gac Sanit. (2021) 35:95&#x2013;8. 10.1016/j.gaceta.2020.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaceta.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7198168</ArticleId><ArticleId IdType="pubmed">32446594</ArticleId></ArticleIdList></Reference><Reference><Citation>Czeisler M&#xc9;, Lane RI, Wiley JF, Czeisler CA, Howard ME, Rajaratnam SMW. Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw Open. (2021) 4:e2037665. 10.1001/jamanetworkopen.2020.37665</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.37665</ArticleId><ArticleId IdType="pmc">PMC7896196</ArticleId><ArticleId IdType="pubmed">33606030</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. (2022) 376:e068993. 10.1136/bmj-2021-068993</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068993</ArticleId><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim SW, Chang HH, Kwon KT, Bae S, Hwang S. Significance and associated factors of long-term sequelae in patients after acute COVID-19 infection in Korea. Infect Chemother. (2021) 53:463&#x2013;76. 10.3947/ic.2021.0022</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2021.0022</ArticleId><ArticleId IdType="pmc">PMC8511373</ArticleId><ArticleId IdType="pubmed">34405592</ArticleId></ArticleIdList></Reference><Reference><Citation>Manthey J, Kilian C, Carr S, Bartak M, Bloomfield K, Braddick F, et al. Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users. J. Subst Abuse Treat Prev Policy. (2021) 16:36. 10.1186/s13011-021-00373-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13011-021-00373-y</ArticleId><ArticleId IdType="pmc">PMC8072737</ArticleId><ArticleId IdType="pubmed">33902668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellos E, Paparrigopoulos T. Substance use during the COVID-19 pandemic: what is really happening? Psychiatriki. (2022) 33:17&#x2013;20. 10.22365/jpsych.2022.072</Citation><ArticleIdList><ArticleId IdType="doi">10.22365/jpsych.2022.072</ArticleId><ArticleId IdType="pubmed">35255473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Janmohamed K, Nyhan K, Martins SS, Cerda M, Hasin D, et al. Substance, use in relation to COVID-19: a scoping review. Addict Behav. (2022) 127:107213. 10.1016/j.addbeh.2021.107213</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addbeh.2021.107213</ArticleId><ArticleId IdType="pmc">PMC8684053</ArticleId><ArticleId IdType="pubmed">34959077</ArticleId></ArticleIdList></Reference><Reference><Citation>Korchia T, Faugere M, Suc N, Garosi A, Andrieu-Haller C, Breyton M, et al. FondaMental advanced centres of expertise in resistant depression (FACETRD) group. Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. Prog Neuropsychopharmacol Biol Psychiatry. (2022) 114:110479. 10.1016/j.pnpbp.2021.110479</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2021.110479</ArticleId><ArticleId IdType="pubmed">34826559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard CE, S&#xfc;tsch C, Bengs S, Deforth M, Buehler KP, Hamouda N, et al. Sex- and gender specific risk factors of post-COVID-19 syndrome: a population-based cohort study in Switzerland. bioRxiv [Preprint]. (2021). 021-04389-z 10.1038/s41586-</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe0; G, Goldoni M, Solinas E, Cavalli C, Tagliaferri S, Ranzieri S, et al. Sex-Related differences in long-COVID-19 Syndrome. J Womens Health. (2022) 31:620&#x2013;30. 10.1089/jwh.2021.0411</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2021.0411</ArticleId><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>